Gamma polyglutamated methotrexate and uses thereof
AssigneeL.E.A.F. Holdings Group LLC
InventorsClet Niyikiza, Victor Mandla Moyo
Life of this patent
Estimating the term…
Abstract
The disclosure relates generally to gamma polyglutamated methotrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated methotrexate, and methods of making and using the gamma polyglutamated methotrexate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).
Claims23
A liposomal composition comprising a gamma polyglutamated methotrexate encapsulated by a liposome, wherein the gamma polyglutamated methotrexate contains 2-10, 4-6, 4, 5, or more than 5 glutamyl groups have a gamma carboxyl linkage, wherein the liposome is pegylated, wherein the liposome does not contain a targeting moiety having specific affinity for a surface antigen on a target cell,
- wherein the liposome does not contain a cell penetrating peptide and does not contain a mitochondria penetrating peptide,
- wherein the liposome has a zeta potential that is less than or equal to zero, between 0 to −150 mV, or between −30 to −50 mV, and
- wherein the liposome is capable of delivering the gamma polyglutamated methotrexate directly into a cell.
Dependencies are inferred from the claim text.